William Blair analyst Sami Corwin has maintained their bullish stance on RARE stock, giving a Buy rating on September 4.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sami Corwin has given his Buy rating due to a combination of factors related to the promising data from Ultragenyx Pharmaceutical’s Phase III study of DTX401, a gene therapy for glycogen storage disease type Ia (GSDIa). The study demonstrated significant reductions in daily cornstarch intake among patients, with a 61% decrease at 96 weeks, which surpassed the clinically meaningful target and showed improvement from earlier results.
Additionally, the therapy’s ability to maintain low hypoglycemia levels and improve fasting tolerance while reducing cornstarch intake highlights its potential long-term benefits. The open-label Japanese cohort further supports these findings, with participants achieving complete elimination of cornstarch intake and reporting enhanced quality of life. These compelling results underscore the transformative potential of DTX401, justifying the Buy rating as the therapy progresses towards Biologics License Application (BLA) completion.
According to TipRanks, Corwin is a 4-star analyst with an average return of 6.5% and a 48.39% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Ultragenyx Pharmaceutical, and PTC Therapeutics.
In another report released on September 4, Cantor Fitzgerald also maintained a Buy rating on the stock with a $105.00 price target.